Eledon Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on June 16, 2021, regarding events occurring on June 15, 2021. Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a Delaware corporation, held its Annual Meeting of Stockholders on this date to vote on corporate governance matters.
Financial Metrics
This filing is a corporate governance report and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity is not provided in this document.
Material Changes
The filing reports the results of stockholder votes rather than financial or operational changes. The key material events are the election of directors and the ratification of the independent auditor.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies. The document strictly details the voting outcomes of the Annual Meeting.
Key Facts for Investor Verification
- Director Election: Stockholders elected three Class I directors (June Lee, M.D., Walter Ogier, and Steven Perrin, Ph.D.) to serve three-year terms expiring in 2024. All nominees received significant majority support with over 8.4 million votes "For" each.
- Auditor Ratification: Stockholders ratified the appointment of KMJ Korbin & Company LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021, with 9,286,240 votes "For" versus 8,941 "Against".
- Broker Non-Votes: There were 844,399 broker non-votes recorded for the director election proposals, which did not affect the outcome as the votes "For" exceeded the threshold required for election.
- Financial Data Absence: Investors should note that this specific filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.